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1. Introduction
The interaction of proteins and drugs affects the 
pharmacological behavior, toxicity, and metabolism 
of drugs. In contrast, the binding of drugs to a certain 
protein may lead to an alteration in the secondary 
structure of the protein. Only a free drug can diffuse from 
the blood to a target (1). Thus, binding of a drug and 
protein affects the metabolism and action of that drug. 
Examining the interaction of a protein and a drug helps to 
understand the pharmacokinetics and pharmacodynamics 
of that drug. 
 Riociguat (Figure 1), a stimulator of redox-sensitive 
soluble guanylate cyclase, is the only drug approved 
for the treatment of inoperable or persistent/recurrent 
chronic thromboembolic pulmonary hypertension (2-
4). After oral administration, riociguat is transported 
through the bloodstream to the tissues and organ, and 
the therapeutic efficacy of riociguat is directly related to 
its free concentration in blood plasma (5). In addition, 
serious adverse events have been noted after riociguat 
monotherapy and are associated with the plasma 
concentration (6). Thus, the ability of riociguat to bind to 
plasma proteins is critical for its metabolism and efficacy. 
To the extent known, the mechanism by which riociguat 
binds to plasma proteins has not been studied thus far. 
 Human serum albumin (HSA) is the prominent 
transport protein in human plasma, and it plays an 
important role in the storage and transportation of 
numerous compounds including drugs and other 
substances (7). HSA consists of three homologous 
domains - I, II and III - each of which is divided into 
two subdomains (A and B). The main binding sites 
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include site I (subdomain IIA), which is marked by 
warfarin, and site II (subdomain IIIA), which is marked 
by ibuprofen (8,9). The ability of a drug to bind to HSA 
is an important factor for its efficacy and metabolism. 
Examining the binding of drugs to HSA may explain 
the structural features that affect the pharmacokinetic 
and pharmacodynamics of those drugs. Therefore, the 
binding interaction of riociguat and HSA needs to be 
promptly examined.
 The current study used fluorescence, Fourier-
transform infrared (FT-IR) spectroscopy, circular 
dichroism (CD), and molecular docking to examine the 
intermolecular interaction between riociguat and HSA. 
The form of binding, the association constant, the change 
in the protein secondary structure, and the site where 
riociguat bound to were determined. Findings should 
have great significance in terms of studying the process 
of storage and transportation of riociguat in the body and 
its mechanism of action and pharmacokinetics.
2. Materials and Methods
2.1. Chemicals and Reagents 
A reference standard of riociguat (≥ 98%) was purchased 
from Ark Pharm, Inc. (Chi., USA). HSA was purchased 
from Solarbio Science & Technology Co. Ltd. (Beijing, 
China). Tris-(hydroxymethyl aminomethane) (Tris) (≥ 
99%) and sodium chloride (≥ 99.5%) were purchased 
from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, 
China). Ibuprofen (≥ 99%) was purchased from Inno 
Chem Science & Technology Co., Ltd. (Beijing, China). 
Warfarin (≥ 98%) was purchased from Adamas Reagent 
Co., Ltd. (Shanghai, China). Methanol (HPLC-grade) 
was purchased from Fisher Chemical Co., Ltd. (Shanghai, 
China). 
2.2. Sample preparation
A stock solution of riociguat (10 mM) was prepared 
in methanol solution. HSA was dissolved in 0.05 M 
Tris-HCl buffer solution containing 0.1 M NaCl (pH 
= 7.4). Both warfarin and ibuprofen were dissolved in 
a mixture of methanol and Tris-HCl buffer solution to 
obtain a concentration of 1.2 × 10-4 M. All solutions 
were prepared at room temperature and stored at 4℃. 
The final concentration of methanol in the test solutions 
was less than 2.4%, so the properties of HSA were not 
affected by methanol (10).
2.3. Fluorescence measurements
A Varian Cary Eclipse Spectrophotometer (Varian, 
Australia) with a 2-mm quartz cell was used to measure 
fluorescence spectra. The excitation wavelength for 
HSA-riociguat was 280 nm, and the emission spectrum 
was recorded from 290 to 450 nm. The widths of the 
excitation and emission slits were both set at 10 nm. The 
quenching effect of riociguat on HSA was investigated 
at three different temperatures of 288 K, 298 K, and 
308 K. A mixture of riociguat and HSA were prepared 
with a constant HSA concentration of 2 μM (11,12). 
The concentration of riociguat varied from 0-12 μM. 
Synchronous fluorescence spectra were recorded at 
different scanning intervals of Δλ (Δλ = 60 nm and 15 
nm) at room temperature. 
2.4. CD measurements
The CD spectra of HSA with or without riociguat 
were recorded using an Applied Photophysics circular 
dichroism spectropolarimeter (Applied Photophysics 
Ltd. Leatherhead, UK). The wavelength range scanned 
was 200-400 nm with a 1-mm quartz cell. The data 
were obtained with an interval of 1 nm and a scan rate 
of 164 nm/min. 
2.5. FT-IR Measurements
FT-IR spectra were recorded using a Nicolet 6700 FT-
IR spectrophotometer (Thermo Nicolet, Madison, 
America). The concentration of HSA was 1 mM and that 
of riociguat was 0.4 mM. The sample solutions were 
placed in a smart ITX diamond sampler. For all spectra, 
100 scans recorded at a resolution of 4 cm-1. Data were 
analyzed using Nicolet OMNIC software. The second 
derivative resolution enhancement was performed 
to determine the position of each peak when peaks 
overlapped, and peaks were fitted using a Gaussian peak 
function. 
2.6. Site marker competitive binding
Site marker competitive binding experiments were 
conducted using warfarin (as site I marker) and ibuprofen 
(as site II marker). In the fluorescence experiments, the 
concentrations of HSA and site markers were both 2 μM, 
while the concentration of riociguat gradually increased 
from 0 to 12 μM. 
2.7. Molecular docking
AutoDock vina 1.1.2 was used to determine how 
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Figure. 1. The structure of riociguat.
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As shown in Figure 2A, the fluorescence intensity of 
HSA decreased gradually with the increase in riociguat 
at around 334 nm. The fluorescence quenching data 
were analyzed using the Stern-Volmer equation (Eq. (1)) 
(20,21).
      F0/F = 1+ KSV [Q] = 1 + Kqt0[Q]            (1)
In the equation, F0 and F are the steady state fluorescence 
intensities in the absence and presence of a quencher, 
respectively. KSV  is the Stern-Volmer quenching constant 
and [Q] is the concentration of the quencher (riociguat). 
Kq is the bimolecular quenching rate constant and t0 is the 
fluorescence lifetime of HSA. The Stern-Volmer plots 
of the fluorescence of HSA quenched with riociguat at 
different temperatures are shown in Figure 2B, and the 
values of KSV and Kq at different temperature are shown 
in Table 1. Results indicated that the mechanism by 
which riociguat quenched the fluorescence of HSA was 
static quenching due to the formation of a riociguat-HSA 
complex.
3.2. Binding constant and thermodynamic parameters
When examining the binding interaction of riociguat 
and HSA, the binding constant (Kb) and the number of 
binding sites (n) can be determined using the equation 
as follow (Eq. (2)) (22).
              F0 -F      log(           ) = logKb + nlog[Q]            (2)
                  F
where Kb is the binding constant and n is the number 
of binding sites for a riociguat-HSA complex. The 
Lineweaver-Burk plots at different temperatures are 
shown in Figure 2C, and the parameters are shown in 
Table 1. The calculated values of n were approximately 
equal to 1, indicating the existence of a single binding 
site for riociguat on HSA. The estimated value of Kb 
was 1.55 × 104 M−1 at 298 K, suggesting that strong 
interaction of riociguat and HSA. 
 Thermodynamic variables were calculated using the 
van't Hoff equation:
                  
 ΔH
     
ΔS      lnK = -        +                   (3)
                   RT      R
      ΔG = ΔH - TΔS                (4)
riociguat bound to HSA (13). The three-dimensional (3D) 
structure of HSA (PDB ID: 2BXB) was downloaded 
from the Protein Data Bank (PDB) (14). The 2D 
structure of riociguat was drawn using ChemBioDraw 
Ultra 12.0 and converted to a 3D structure using the 
software ChemBio3D Ultra 12.0. The AutoDockTools 
1.5.6 package was used to generate docking input files 
(15,16). A ligand was modified for docking by merging 
non-polar hydrogen atoms and defining rotatable bonds. 
The search grid of the HSA site I (subdomain IIA) was 
identified as center_x: 4.412, center_y: -8.174, and 
center_z: 8.25 with dimensions of size_x: 15, size_y: 15, 
and size_z: 15. The value of exhaustiveness was set to 
20. The best-scoring binding mode was modeled on the 
software PyMoL 1.7.6 (1.3r1, DeLano Scientific LLC, 
South San Francisco, USA) (17).
3. Results
3.1. Fluorescence measurements
Fluorescence quenching is considered to be an effective 
and sensitive method with which to investigate the 
interaction of small molecules and proteins. The intrinsic 
fluorescence of HSA is mainly due to tryptophan (Trp), 
tyrosine (Tyr), and phenylalanine (Phe) residues. Shifts 
in λmax and fluorescence intensity, which are mainly 
attributed to changes in the position of the Trp residues, 
were used to study HSA-riociguat interaction (18,19). 













































Figure 2. The fluorescence quenching spectra of HSA 
(2 μM) with different concentrations of riociguat at the 
excitation wavelength (280 nm) in Tris-HCl (pH 7.4). 
Riociguat solutions 1 to 8 had a concentration of 0, 1, 2, 4, 
6, 8, 10, and 12 μM (A). Ster-Volmer plots for HSA (2 μM) 
quenched with riociguat at different temperatures (B). Plots of 
Log [(F0 – F)/F] vs. Log [Q] for HSA (2 μM) quenched with 
riociguat at different temperatures (C). The van't Hoff plot for 
the calculation of different thermodynamic parameters (D).
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where K is the binding constant at temperature T, and 
the R is the gas constant. The van't Hoff plot for the 
interaction of riociguat and HSA is shown in Figure 2D, 
and the thermodynamic parameters are shown in Table 
1. If the ΔH and ΔS are > 0, then the binding force is 
hydrophobic interaction. A negative ΔH and ΔS usually 
indicates the presence of hydrogen bonding and/or 
van der Waals forces. If ΔH is < 0 and ΔS is > 0, an 
electrostatic force is identified (23-26). In the current 
study, ΔG was negative, so the binding of riociguat to 
HSA was a spontaneous process. The positive values 
of both ΔH and ΔS revealed that the main force was 
hydrophobic interaction when riociguat bound to HSA.
3.3. Melanoma specimens
Characteristic information on Tyr and Trp residues 
can be obtained from synchronous fluorescence 
spectroscopy when the scanning interval Δλ (Δλ = λem 
- λex) is set at 15 and 60 nm (27,28). Figure 3A and 3B 
show the synchronous fluorescence spectra of HSA 
with various concentrations of riociguat, and the spectra 
were recorded with Δλ = 15 and 60 nm, respectively. A 
slight red shift in the maximum emission was observed 
at Δλ = 60 nm, suggesting that the hydrophobic 
environment surrounding Trp decreased slightly with 
the addition of riociguat. The intensities of both Trp and 
Tyr residues decreased, indicating that the quenching of 
HSA involved Trp and Tyr. Conformation of the protein 
changed upon interaction with riociguat. 
3.4. CD spectroscopy
The CD spectra of HSA with and without riociguat are 
shown in Figure 3C. CD was calculated using the mean 
residue ellipticity (MRE) in deg cm2 dmol−1 according 
to the following equation:
                           θobs (mdeg)      MER208 =                                         (5)
                           10 • n • l • Cp
                             -MER208 -4000 
      α-helix(%) =                                    (6)
                              33000 - 4000
where MER208 is the mean residue ellipticity at 208 nm, 
Cp is the molar concentration of HSA, n is the number 
of amino acid residues (585), l is the path length (0.1 
cm). 4,000 is the MRE of the β-form and random coil 
conformation cross at 208 nm, and 33,000 is the MRE 
value of a pure α-helix at 208 nm. Using the above 
equation, the α-helicity in free HSA was 55.95%. After 
the addition of riociguat at 6 and 12 µM, the α-helical 
content increased from 55.95% to 58.01% and then 
to 59.49%. The structure of albumin was altered by 
riociguat. 
3.5. FT-IR Spectra
To further investigate the changes in the structure of 
HSA, second derivative resolution enhancement and 
cure fitting were performed, as shown in Figure 4. 
Figure 4A and 4B show the FT-IR fitting curves of 
HSA in the absence and presence of riociguat in Tris-
HCl buffer in the region of 1,700-1,600 cm-1. Changes in 
peak positions and peak shapes indicated that riociguat 
induced a slight change in the secondary structure of 
HSA with binding toward the C=O groups. According 
to the quantitative analysis of the secondary structure, 
the α-helix content increased 8.16% as a result of the 
addition of riociguat. These results coincided with the 
CD spectra. 
3.6. Site marker competitive binding
Two main specific drug-binding sites of HSA have 
previously been reported, including site I (subdomain 
IIA) and site II (subdomain IIIA). In the current study, 
warfarin (as site I marker) and ibuprofen (as site II 
marker) were used as site markers to investigate the 
binding site of riociguat on HSA. KSV and Kb in a 
system of HSA and site markers were recorded as the 
concentration of riociguat increased, and the results are 
Figure 3. Synchronous fluorescence of HSA (2 μM) with 
different concentrations of riociguat at the excitation 
wavelength (280 nm) at room temperature when Δλ = 15 
nm (A) and Δλ = 60 nm (B) in Tris-HCl (pH 7.4). Riociguat 
solutions 1 to 8 had a concentration of 0, 1, 2, 4, 6, 8, 10, and 
12 μM. CD spectra of HSA (2 μM) in the presence of riociguat 
(12 μM) in Tris-HCl (pH 7.4) (C).
Figure 4. Second derivative resolution enhancement and 
curve-fitted amide I region (1,700-1,600 cm−1) for HSA (0.1 
mM) in Tris-HCl buffer solution (pH = 7.40) in the absence 
(A) and presence of riociguat (B).
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shown in Table 2. Kb and KSV markedly decreased in the 
presence of warfarin while the values were almost the 
same in the presence of ibuprofen. Results indicated 
that riociguat and warfarin competitively bound 
to HSA. The binding site of riociguat on HSA was 
primarily located on site I of HSA.  
3.7. Molecular docking
Figure 5 shows the binding site of the HSA and the 
docking results. Riociguat docked in site I (subdomain 
IIA), and the overall view is shown in Figure 5A. 
Riociguat assumed a compact conformation to enter 
of the pocket of HSA, and a detailed view is shown in 
Figure 5B. The 2-fluorophenyl of riociguat stretched 
into the hydrophobic pocket that consisted of Leu-
260, Ala-261, Ile-264, Ile-290, and Ala-291, forming 
a stable hydrophobic bond. The pyrimidine scaffold of 
riociguat participated in π-π stacking interaction with 
the residue Tyr-150. In addition, cation-π interactions 
between riociguat and the residues Lys-199, Arg-222, 
and Arg-257 were observed. Importantly, five hydrogen 
bond interactions were identified between riociguat and 
the residues Tyr-150, Glu-153, and Arg-257 of HSA. 
The above molecular simulations provided a good 
structural basis on which to explain the quenching of 
HSA fluorescence in the presence of riociguat.
4. Discussion
HSA is widely used in biophysical, biochemical, and 
physicochemical studies since it has been extensively 
studied with different small molecules and its primary 
structure is well known. The weak binding of ligands 
to HSA results in a short lifetime or poor distribution 
of compounds since strong binding leads to a decrease 
in the concentration of free ligands in plasma. Thus, 
the interaction between a drug and HSA will affect its 
metabolism, distribution, toxicity, and elimination from 
the circulation. Riociguat is rapidly absorbed and its 
concentration subsequently decreases. It has a terminal 
half-life in the range of 5 to 10 hours, and its plasma 
binding rate is approximately 95% (29). The current 
study of the interaction between riociguat and HSA will 
help to understand the process of riociguat metabolism.
 Fluorescence quenching is a decrease in the 
quantum yield of fluorescence induced by a variety 
of molecular interactions with a quencher molecule. 
Protein conformational transitions, biomolecule binding, 
denaturation, and other factors are responsible for the 
decrease in the intrinsic fluorescence of protein. Thus, 
fluorescence quenching is widely used to explore the 
binding of biomolecules and active small molecules. 
Fluorescence quenching can be caused by collisions 
or by ground-state complex formation between a 
fluorophore and a quencher. The former is referred to 
as dynamic quenching while the latter is referred to as 
static quenching (21). If the value of KSV decreases with 
increasing temperature and the kq value is much greater 
than the maximum diffusion collision quenching rate 
constant (2.0 × 1010 L/mol s) of HSA with a variety 
of quenchers (30,31), then the mechanism by which a 
compound quenches the fluorescence of albumin is static 
quenching due to the formation of a compound-HSA 
complex. In the current study, riociguat bound to HSA 
via static quenching. 
 This study used fluorescence, FT-IR spectroscopy, 
CD spectroscopy, and molecular docking to conduct the 
first detailed investigation of the interaction between 
riociguat and HSA. Results indicated that riociguat 
effectively quenched the intrinsic fluorescence of 
HSA via static quenching. The binding process was 
spontaneous, and the main force was hydrophobic 
interaction. Conformational results from CD and FT-
IR spectra revealed that the binding of riociguat to HSA 
induced some micro-environmental and conformational 
changes. The current results will help to better understand 
aspects of pharmacokinetics such as drug metabolism, 
excretion, and distribution.
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